Chang-Yu Huang

Chang-Yu Huang

Auto-generated profile, based on publicly available information

Chang-Yu Huang

Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CCChih-Wei Chen
Chih-Wei Chen
HWHong-Ling Wang
Hong-Ling Wang
CHChing-Wen Huang
Ching-Wen Huang
CHChang-Yu Huang
Chang-Yu Huang
WLWai Keong Lim
Wai Keong Lim
ZCZee-Fen Chang
Zee-Fen Chang
Significance: It is known that nutrient starvation stimulates mitochondrial fusion for cell survival. In this study, a homozygous mutation in the NME3 gene, which encodes an NDP kinase, was identified in a fatal neurodegenerative disorder. Cells derived from the patient were deficient of NME3 and intolerant to glucose starvation. Patient cells were used to demonstrate that NME3 rescued cell survival by two separate functions, namely stimulation of mitochondrial fusion and NDP kinase activity. Since mitochondrial dynamics and energy efficiency are important for neuronal development, our data suggest a link between two functions of NME3 and a fatal neuronal disorder.

13 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
CCChih-Wei Chen
Chih-Wei Chen
CSChi Su
Chi Su
CHChang-Yu Huang
Chang-Yu Huang
XHXuan-Rong Huang
Xuan-Rong Huang
XCXiaojing Cuili
Xiaojing Cuili
ZCZee-Fen Chang
Zee-Fen Chang
NME3 is a member of the nucleoside diphosphate kinase (NDPK) family localized on the mitochondrial outer membrane (MOM). Here, we report a role of NME3 in hypoxia-induced mitophagy dependent on its active site phosphohistidine but not the NDPK function. Mice carrying a knock-in mutation in the Nme3 gene disrupting NME3 active site histidine phosphorylation are vulnerable to ischemia/reperfusion-induced infarction and develop abnormalities in cerebellar function. Our mechanistic analysis reveals that hypoxia-induced phosphatidic acid (PA) on mitochondria is essential for mitophagy and the interaction of DRP1 with NME3. The PA binding function of MOM-localized NME3 is required for hypoxia-induced mitophagy. Further investigation demonstrates that the interaction with active NME3 prevents DRP1 susceptibility to MUL1-mediated ubiquitination, thereby allowing a sufficient amount of active DRP1 to mediate mitophagy. Furthermore, MUL1 overexpression suppresses hypoxia-induced mitophagy, which is reversed by co-expression of ubiquitin-resistant DRP1 mutant or histidine phosphorylatable NME3. Thus, the site-specific interaction with active NME3 provides DRP1 a microenvironment for stabilization to proceed the segregation process in mitophagy.

1 July 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CHChang-Yu Huang
Chang-Yu Huang
YCYee-Chun Chen
Yee-Chun Chen
BWBetty A. Wu-Hsieh
Betty A. Wu-Hsieh
JFJim-Min Fang
Jim-Min Fang
ZCZee-Fen Chang
Zee-Fen Chang
The yeast Candida albicans is the most prevalent opportunistic fungal pathogen in humans. Drug resistance among C. albicans isolates poses a common challenge, and overcoming this resistance represents an unmet need in managing this common pathogen. Here, we investigated CDC8, encoding thymidylate kinase (TMPK), as a potential drug target for the management of C. albicans infections. We found that the region spanning amino acids 106–123, namely the Ca-loop of C. albicans TMPK (CaTMPK), contributes to the hyperactivity of this enzyme compared with the human enzyme (hTMPK) and to the utilization of deoxyuridine monophosphate (dUMP)/deoxy-5-fluorouridine monophosphate (5-FdUMP) as a substrate. Notably, expression of CaTMPK, but not of hTMPK, produced dUTP/5-FdUTP–mediated DNA toxicity in budding yeast (Saccharomyces cerevisiae). CRISPR-mediated deletion of this Ca-loop in C. albicans revealed that the Ca-loop is critical for fungal growth and susceptibility to 5-fluorouridine (5-FUrd). Of note, pathogenic and drug-resistant C. albicans clones were similarly sensitive to 5-FUrd, and we also found that CaTMPK is essential for the growth of C. albicans. In conclusion, these findings not only identified a target site for the development of CaTMPK-selective drugs, but also revealed that 5-FUrd may have potential utility as drug for managing C. albicans infections.

10 July 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
CHChang-Yu Huang
Chang-Yu Huang
YCYin-Hsuan Chung
Yin-Hsuan Chung
SWSheng-Yang Wu
Sheng-Yang Wu
HWHsin-Yen Wang
Hsin-Yen Wang
CLChih-Yu Lin
Chih-Yu Lin
ZCZee-Fen Chang
Zee-Fen Chang
Bcr-Abl transformation leads to chronic myeloid leukemia (CML). The acquirement of T315I mutation causes tyrosine kinase inhibitors (TKI) resistance. This study develops a compound, JMF4073, inhibiting thymidylate (TMP) and cytidylate (CMP) kinases, aiming for a new therapy against TKI-resistant CML. In vitro and in vivo treatment of JMF4073 eliminates WT-Bcr-Abl-32D CML cells. However, T315I-Bcr-Abl-32D cells are less vulnerable to JMF4073. Evidence is presented that ATF4-mediated upregulation of GSH causes T315I-Bcr-Abl-32D cells to be less sensitive to JMF4073. Reducing GSH biosynthesis generates replication stress in T315I-Bcr-Abl-32D cells that require dTTP/dCTP synthesis for survival, thus enabling JMF4073 susceptibility. It further shows that the levels of ATF4 and GSH in several human CML blast-crisis cell lines are inversely correlated with JMF4073 sensitivity, and the combinatory treatment of JMF4073 with GSH reducing agent leads to synthetic lethality in these CML blast-crisis lines. Altogether, the investigation indicates an alternative option in CML therapy.

11 October 2021 in Analytical Chemistry
Verified
Journal Article
Closed access
HWHsin-Yen Wang
Hsin-Yen Wang
PHPeng Hsin
Peng Hsin
CHChang-Yu Huang
Chang-Yu Huang
ZCZee-Fen Chang
Zee-Fen Chang

23 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
CHChang-Yu Huang
Chang-Yu Huang
YCYin-Hsuan Chung
Yin-Hsuan Chung
SWSheng-Yang Wu
Sheng-Yang Wu
HWHsin-Yang Wang
Hsin-Yang Wang
ZLZhi-Yu Lin
Zhi-Yu Lin
ZCZee-Fen Chang
Zee-Fen Chang
T315I mutation of Bcr-Abl in chronic myeloid leukemia (CML) leads to therapeutic resistance. It is known that Bcr-Abl transformation causes ROS-induced DNA damages and replication stress, which can be exploited for anti-nucleotide therapy. We developed a small compound, JMF4073, which inhibited pyrimidylate kinases and selectively eliminated Bcr-Abl-transformed, but not untransformed myeloid cells, due to dTTP exhaustion and ROS-induced replication stress. However, T315I-Bcr-Abl-transformed cells were less vulnerable to JMF4073 because of higher dTTP pool and low replication stress. Unlike WT-Bcr-Abl-transformed cells, T315I-Bcr-Abl cells lacked Sirt1- regulated OXPHOS with increased glutamine flux to reductive carboxylation in TCA cycle and glutathione synthesis. Blocking mitochondrial pyruvate carrier (MPC) by UK-5099 reduced NADH and glutathione levels with replication stress induction, thereby converting T315I-Bcr-Abl cells sensitive to JMF4073 with dTTP and dCTP depletion. The combination of JMF4073 with UK-5099 showed in vivo eradication of T315I-Bcr-Abl-CML. These data reveal that T315I mutation causes reductive metabolic shifts in Bcr-Abl-CML, and demonstrate the therapeutic option by co-targeting MPC and pyrimidylate kinases.